|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400086870 |
|
最近更新日期: Date of Last Refreshed on: |
2024-07-12 16:38:52 |
|
注册时间: Date of Registration: |
2024-07-12 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
清肺散结方治疗肺结节(Lung-RADs 2-3类)的随机对照临床研究 |
|
Public title: |
A randomized controlled clinical study on the treatment of pulmonary nodules (Lung RADs 2-3) with Qingfei Sanjie formula |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
清肺散结方治疗肺结节(Lung-RADs 2-3类)的随机对照临床研究 |
|
Scientific title: |
A randomized controlled clinical study on the treatment of pulmonary nodules (Lung RADs 2-3) with Qingfei Sanjie formula |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
陈远彬 |
研究负责人: |
林琳 |
|
Applicant: |
Yuanbin Chen |
Study leader: |
Lin lin |
|
申请注册联系人电话: Applicant telephone: |
+86 159 2017 4645 |
研究负责人电话:
Study leader's |
+86 81887233 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
chenyuanbin110@163.com |
研究负责人电子邮件: Study leader's E-mail: |
drlinlin620@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广东省广州市越秀区大德路111号 |
研究负责人通讯地址: |
广东省广州市越秀区大德路111号 |
|
Applicant address: |
111 Dade Road, Yuexiu District, Guangzhou City, Guangdong Province |
Study leader's address: |
111 Dade Road, Yuexiu District, Guangzhou City, Guangdong Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
广东省中医院 |
||
|
Applicant's institution: |
Guangdong Provincial Hospital of Traditional Chinese Medicine |
||
|
研究负责人所在单位: |
广东省中医院 |
||
|
Affiliation of the Leader: |
Guangdong Provincial Hospital of Traditional Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
ZF2024-012-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广东省中医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Guangdong Provincial Hospital of Traditional Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-02-02 00:00:00 | ||
|
伦理委员会联系人: |
李晓彦 |
||
|
Contact Name of the ethic committee: |
Xiaoyan Li |
||
|
伦理委员会联系地址: |
广东省广州市越秀区大德路111号 |
||
|
Contact Address of the ethic committee: |
111 Dade Road, Yuexiu District, Guangzhou City, Guangdong Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 8188 7233 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
广东省中医院 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Guangdong Provincial Hospital of Traditional Chinese Medicine |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广东省广州市越秀区大德路111号 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
111 Dade Road, Yuexiu District, Guangzhou City, Guangdong Province |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
self-financing |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
肺结节 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
pulmonary nodule |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
评估清肺散结方治疗肺结节的有效性及安全性,为临床中医药治疗肺结节提供参考 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
Evaluate the effectiveness and safety of Qingfei Sanjie Formula in treating pulmonary nodules, providing reference for clinical traditional Chinese medicine treatment of pulmonary nodules |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
①符合肺结节的西医诊断标准,且肺结节Lung-RADs分级归为2类及3类; ②胸部CT发现肺结节,且近3月内结节稳定无增长或消散; ③中医辨证属气虚湿热郁结证; ④年龄在18-85岁之间,性别不限; ⑤自愿参加,沟通与理解能力良好,并愿意配合随访; ⑥患者签署本研究知情同意书。 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
①Meets the Western medical diagnostic criteria for pulmonary nodules, and the Lung RADs grading of pulmonary nodules is classified as Class 2 and Class 3 ②Chest CT reveals pulmonary nodules, which have remained stable without significant growth or disappearance in the past three months ③Traditional Chinese Medicine syndrome differentiation belongs to the syndrome of Qi deficiency, dampness and heat stagnation ④Age between 18 and 85 years old, regardless of gender ⑤Voluntary participation, good communication and understanding skills, and willingness to cooperate with others ⑥All patients participating in this study should sign the informed consent forms |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
①评估为高危结节,Lung-RADS分级归为4类及以上,恶性概率>5%,具有外科治疗指征者,或已行肺部切除手术者; ②考虑为转移性肺结节者; ③排除合并其它呼吸道疾病者(如慢阻肺、支扩、社区获得性肺炎、活动性肺结核等); ④中医辨证为脾胃虚寒证者,表现为以下三种情况之一:1)胃脘胀满或隐痛,胃部喜按喜暖,大便稀溏,乏力,舌质淡,边有齿痕;2)胃脘痞满,遇冷加重,嘈杂反酸,口干口苦,肢冷便溏;3)大便时溏时泻,饮食稍有不慎即发或加重,舌质淡; ⑤合并心脑血管、肝、肾、血液等严重原发性疾病或肿瘤疾病的患者; ⑥入组前已使用中药或西药抗炎药治疗肺结节超过4周者; ⑦正在或近3个月内曾接受可能影响肺结节的其他临床试验者; ⑧不愿意接受观察措施或因精神疾病不能合作者; ⑨对治疗方案内所含药物过敏者; ⑩妊娠、计划妊娠和哺乳期患者 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
①Evaluated as a high-risk nodule, classified as Lung RADS grade 4 or above, with a malignancy probability greater than 5%, indicating surgical treatment, or having undergone pulmonary resection; ②Consider metastatic pulmonary nodules; ③patient complicated with other serious respiratory diseases, such as chronic obstructive pulmonary disease, bronchiectasis, community acquired pneumonia, and active tuberculosis; ④TCM syndrome differentiation of spleen and stomach weakness is manifested as one of the following three conditions: 1)epigastric distension or dull pain, stomach preference for warm, loose stools, fatigue, weak tongue, tooth marks on the side; 2)gastric epigastric fullness, aggravated by cold, noisy acid reflux, dry mouth and bitter mouth, cold limbs and loose stool; 3)loose stool when diarrhea, the diet is slightly careless that hair or aggravate, weak tongue; ⑤Patients who took Chinese herbal medicine, Chinese patent medicine that had the effect of clearing heat and reducing phlegm and relieving cough or had the antibacterial effect clearly defined by modern pharmacology within 48 hours before enrolled; ⑥Patients who have been treated with traditional Chinese medicine or Western anti-inflammatory drugs for pulmonary nodules for more than 4 weeks prior before enrolled; ⑦patients who have participated in or are participating in other clinical trials within the last 3 months; ⑧patients who are unwilling to accept observation measures or unable to cooperate due to mental illness; ⑨patients with severe allergic reaction, or known allergic history to Qingfei Sanjie granules or placebo ingredients; ⑩pregnancy, planned pregnancy or lactation women. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-03-01 00:00:00至 To 2029-03-07 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2024-03-07 00:00:00 至 To 2026-03-07 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
简单随机,应用软件生成随机数字表 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Simple randomization, use software to generate random number table |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
双盲,对研究者与患者均设盲 |
|
Blinding: |
Double blind, with blinding for both researchers and patients |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
暂未确定 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Not yet determined |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
病例记录表 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |